Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis
Clinical Pharmacology and Therapeutics, Volume 90, No. 3, Year 2011
Notification
URL copied to clipboard!
Description
We performed a prospective comparative study to examine, from a pharmacogenetics perspective, the effect of rifampicin (RIF) on long-term efavirenz (EFV) autoinduction and kinetics. In a study population of patients with HIV receiving EFV with RIF (arm 2, n = 54) or without RIF (arm 1, n = 128 controls), intraindividual and interindividual plasma EFV and 8-hydroxyefavirenz levels were compared at weeks 4 and 16 of EFV therapy. In arm 2, RIF was initiated 4 weeks before starting EFV. In controls (arm 1), the plasma EFV was significantly lower whereas 8-hydroxyefavirenz was higher at week 16 as compared to week 4. By contrast, there were no significant differences in plasma EFV and 8-hydroxyefavirenz concentrations over time in arm 2. At week 4, the plasma EFV concentration was significantly lower in arm 2 as compared to arm 1, but no significant differences were observed by week 16. When stratified by CYP2B6 genotype, significant differences were observed only with respect to CYP2B61/1 genotypes. Ours is the first report of the CYP2B6 genotype-dependent effect of RIF on long-term EFV autoinduction. © 2011 American Society for Clinical Pharmacology and Therapeutics.
Authors & Co-Authors
Ngaimisi, Eliford
Sweden, Stockholm
Karolinska Universitetssjukhuset
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Mugusi, Sabina Ferdinand
Tanzania, Dar es Salaam
Muhimbili National Hospital
Sweden, Stockholm
Karolinska Universitetssjukhuset
Minzi, Omary Mashiku Sylivester
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Sasi, Philip Galula
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Riedel, Klaus Dieter
Germany, Heidelberg
Universität Heidelberg
Suda, Akira
Sweden, Stockholm
Karolinska Universitetssjukhuset
Ueda, Nobuhisa
Sweden, Stockholm
Karolinska Universitetssjukhuset
Janabi, Mohamed Y.
Tanzania, Dar es Salaam
Muhimbili National Hospital
Mugusi, Ferdinand M.
Tanzania, Dar es Salaam
Muhimbili University of Health and Allied Sciences
Haefeli, Walter Emil
Germany, Heidelberg
Universität Heidelberg
Bertilsson, Leif N.
Sweden, Stockholm
Karolinska Universitetssjukhuset
Burhenne, Jürgen
Germany, Heidelberg
Universität Heidelberg
Aklillu, Eleni
Sweden, Stockholm
Karolinska Universitetssjukhuset
Statistics
Citations: 101
Authors: 13
Affiliations: 4
Identifiers
Doi:
10.1038/clpt.2011.129
ISSN:
00099236
e-ISSN:
15326535
Research Areas
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study
Cohort Study